Goldman Small Cap Research disclosed that it released a new research article on Pharmacyte Biotech Inc (OTCMKTS:PMCB). It is a sponsored research article on the company that states one of the undisclosed stories behind the company’s success.
It talks about the formation of the International Diabetes Consortium that has resulted in unprecedented and unique collaboration on diabetes research supporting expedited clinical trials. It is a 16-member group and includes top tier scientists and doctors active in the segment of diabetes research and treatment. The consortium members are leading Pharmacyte diabetes research projects in over half a dozen universities in Asia and Europe.
The research firm further stated that preclinical research and animal trials are conducted one at a time. The group multiple trials are being implemented at the same time with different designs and goals in order to boost the R&D process. The steps should considerably minimize the time to human clinical studies.
The research firm added that Pharmacyte has exclusive rights to utilize Melligen cells to cure diabetes which in recent trials have shown that they could reverse diabetic condition in treated mice. As of now, the expert team is committed to formulate a treatment for insulin-dependent patients using company’s Cell-in-a-Box® technology combined with Melligen Cells. The members are using their expertise and data to achieve the objective.
In the article, the research firm stated that the value proposition provided Pharmacyte in the Consortium’s initiatives is clear. As per the firm, a higher valuation should be considered each time the company completes an important research stage, which is expected in the coming quarters.
In last trading session, the stock price of Pharmacyte gained more than 1% to close the trading session at $0.162. The gains came at a share volume of 2.07 million lower than the average share volume of 5.21 million.